Towards a pathway definition of Parkinson's disease: A complex disorder with links to cancer, diabetes and inflammation

Neurogenetics

Volumn 9, Issue 1, 2008, Pages 1-13

  Moran, Linda B ^a   Graeber, Manuel B ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Aposklesis; Expression analysis; Lewy bodies; Microarrays; Network medicine; Neurodegeneration; Synaptic dysfunction

Indexed keywords

CLOZAPINE; COCAINE; HALOPERIDOL; PACLITAXEL; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN GENOME; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SEX CHROMOSOME;

DATABASES, GENETIC; DIABETES COMPLICATIONS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; INFLAMMATION; MODELS, GENETIC; MODELS, NEUROLOGICAL; NEOPLASMS; NERVE NET; PARKINSON DISEASE;

PARKINSONIA;

EID: 38649121744     PISSN: 13646745     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10048-007-0116-y     Document Type: Article

References (47)

1. Tretiakoff C (1919) Contribution à l'étude de l'anatomie du locus niger de Soemmering avec quelques déductions relatives à la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson. Thèse de Paris
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
3. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7:1-11
4. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM (2005) Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62:917-921
5. Zhang Y, James M, Middleton FA, Davis RL (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137:5-16
6. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21:305-313
7. Moran LB, Durrenberger PF, Pearce RK, Graeber MB (2007) Two new molecular markers of Lewy bodies in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 78(9) (Abs ABN Spring Scientific Meeting, Cambridge 2007)
8. Moran LB, Hickey L, Michael GJ, Derkacs M, Christian LM, Kalaitzakis ME, Pearce RK, Graeber MB (2007) Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathol DOI 10.1007/s00401-007-0309-3
9. West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson's disease and cancer. Trends Neurosci 28:348-352
10. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7:139-148
11. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci USA 103:1661-1668
12. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38:333-347
13. Wersinger C, Sidhu A (2006) An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem 13:591-602
14. McGeer PL, McGeer EG (2007) Glial reactions in Parkinson's disease. Mov Disord DOI 10.1002/mds.21751
15. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14
16. Ton TG, Heckbert SR, Longstreth WT, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 21:964-969
17. Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM (2007) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193-196
18. Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, Dexter DT, Pearce RK, Graeber MB (2007) Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 113:253-263
19. Yuryev A, Mulyukov Z, Kotelnikova E, Maslov S, Egorov S, Nikitin A, Daraselia N, Mazo I (2006) Automatic pathway building in biological association networks. BMC Bioinformatics 7:171
20. Alibes A, Yankilevich P, Canada A, Diaz-Uriarte R (2007) IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics 8:9
21. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, Frosch MP, Standaert DG (2007) Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis 26:606-614
22. Bower JH, Muenter MD (1995) Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma. Mov Disord 10:681-682
23. Boranic M, Raci F (1979) A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 31:124-125
24. Jonsson PF, Bates PA (2006) Global topological features of cancer proteins in the human interactome. Bioinformatics 22:2291-2297
25. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL (2007) The human disease network. Proc Natl Acad Sci USA 104:8685-8690
26. Loscalzo J, Kohane I, Barabasi AL (2007) Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 3:124
27. Papazoglu C, Mills AA (2007) p53: at the crossroad between cancer and ageing. J Pathol 211:124-133
28. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103:15091-15096
29. Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789
30. Kim RH, Mak TW (2006) Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 94:620-624
31. Zanetti R, Loria D, Rosso S (2006) Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16:201-206
32. Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69:1542-1550
33. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69:125-130
34. Ristow M (2004) Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82:510-529
35. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 12:185-189
36. Arvanitakis Z, Wilson RS, Bienias JL, Bennett DA (2007) Diabetes and parkinsonian signs in older persons. Alzheimer Dis Assoc Disord 21:144-149
37. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J (2007) Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30:842-847
38. Xu J, Li Y (2006) Discovering disease-genes by topological features in human protein-protein interaction network. Bioinformatics 22:2800-2805
39. Barabasi AL (2007) Network medicine-from obesity to the "diseasome". N Engl J Med 357:404-407
40. Graeber MB, Moran LB (2002) Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol 12:385-390
41. Klein JA, Ackerman SL (2003) Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 111:785-793
42. Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R (2007) Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 5:e39
43. Ren Y, Liu W, Jiang H, Jiang Q, Feng J (2005) Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 280:34105-34112
44. Jiang Q, Yan Z, Feng J (2006) Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J Biol Chem 281:29391-29400
45. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976
46. Croisier E, Graeber MB (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 112:517-530
47. Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, Zlotnik A (2006) Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7:67-80